Acute respiratory distress syndrome

Dr. Sham Dholakia joins GEn1E Lifesciences as Chief Medical Officer, as it further scales its AI/ML platform, portfolio and partnerships

Retrieved on: 
Wednesday, December 14, 2022
Immunology, University of Oxford, Acute respiratory distress syndrome, PALO, Pharmacology, 2021 Essex County Council election, Patient, Sham, Knowledge, HIV disease progression rates, AI, Nextgen, CMO, Data analysis, Inflammation, Growth, University, Machine learning, Imperial College London, Cybook Gen1, Scientific Research Publishing, Transplant, Algorithm, Pharmaceutical industry, Medical device

PALO ALTO, Calif., Dec. 14, 2022 /PRNewswire/ -- A clinical-stage, next-generation techbio company, developing multitarget, novel and targeted immunomodulatory therapies for rare and inflammatory diseases, today announces the appointment of Dr. Sham Dholakia as the Chief Medical Officer.

Key Points: 
  • GEn1E has created a differentiated "Platform-in-a-Mechanism" model that uses AI and Machine Learning across the entire end-to-end drug development cycle.
  • Dr. Sham Dholakia, an accomplished transplant surgeon trained at the University of Oxford, joins GEn1E with more than 15 years of clinical experience in the hospital, pharmaceutical and diagnostic industries.
  • Dr. Sham Dholakia, incoming CMO of GEn1E commented "Uncontrolled inflammation is the core of disease progression and poor clinical outcomes.
  • GEn1E Lifesciences is based in Palo Alto, CA, with a laboratory in Mountain View, CA.

Bragar Eagel & Squire, P.C. Is Investigating Veru, Twist, and Leidos and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, December 3, 2022
Acute respiratory distress syndrome, Foreign Corrupt Practices Act, Food, Patient, Twist, DNA microarray, NYSE, Federal Advisory Committee Act, LDOS, Advisory Committee, Instil, COVID-19, News, MCI Inc., Silicon, Private investigator, Audit, P.C, Bankruptcy, Leidos

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Specifically, the Advisory Committee voted 8-5 that the known and potential benefits of sabizabulin do not outweigh its known and potential risks.
  • The subpoena requested documents relating to the Company's internal investigation that Leidos disclosed in its 10-K filed on February 15, 2022.
  • For more information on the Leidos investigation go to: https://bespc.com/cases/LDOS
    About Bragar Eagel & Squire, P.C.

Therma Bright Invests in the Development of Novel Treatments for COVID-19, Asthma, and Chronic Obstructive Pulmonary Disease (COPD)

Retrieved on: 
Thursday, December 1, 2022
COVID-19, Medical school, ROAD, University, Cell, University of California, Davis, Pneumonia, Pain, Chronic lung disease, COPD, Degenerative disease, Acquisition, Patient, Pulmonology, Itch, Chronic obstructive pulmonary disease, FSE, Interstitial lung disease, Cell proliferation, JNX, Research, FDA, Inflammation, Drug development, UCD, COVID, Asthma, School, Therapy, UCAN, UC, Infarction, Stroke, Critical Care Medicine (journal), Acute respiratory distress syndrome, Office for National Statistics, Pharmaceutical industry, Medicine, Therma

Statins have been used clinically to treat high cholesterol levels which protect patients from heart attacks and strokes for over 35 years.

Key Points: 
  • Statins have been used clinically to treat high cholesterol levels which protect patients from heart attacks and strokes for over 35 years.
  • When delivered via the inhaled route, the statins are targeted to the site of disease activity for greater therapeutic benefit.
  • As well, we look forward to the promise that these statin treatments provide for chronic lung diseases including asthma and COPD."
  • Therma Bright Inc. trades on the TSXV (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX).

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Veru Inc. – VERU

Retrieved on: 
Monday, November 28, 2022
COVID-19, Food, Patient, News, Defense Department Advisory Committee on Women in the Services, Advisory Committee, Acute respiratory distress syndrome, Pharmaceutical industry

NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. (Veru or the Company) (NASDAQ:VERU).

Key Points: 
  • NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. (Veru or the Company) (NASDAQ:VERU).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Veru and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Is Investigating Veru, Twist, Leidos, and DLocal and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, November 28, 2022
COVID-19, DNA microarray, Foreign Corrupt Practices Act, Silicon, Twist, Food, LDOS, Muddy Waters, Patient, Research report, Instil, MCI Inc., News, NYSE, Federal Advisory Committee Act, DLO, Acute respiratory distress syndrome, Advisory Committee, Renewable energy, Audit, Private investigator, P.C, Leidos, Bankruptcy

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Specifically, the Advisory Committee voted 8-5 that the known and potential benefits of sabizabulin do not outweigh its known and potential risks.
  • On this news, Verus stock price fell sharply during intraday trading on November 10, 2022.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Fox, Instil, Veru, and Twist and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, November 22, 2022
Trump, COVID-19, Defamation, Fox News, Smartmatic, DNA microarray, Silicon, Food, Twist, Fox Corporation, Patient, FOX, FOXA, Murdoch family, Instil, Fox, Dominion Voting Systems, MCI Inc., News, Delaware Superior Court, Tobacco Products Scientific Advisory Committee, Acute respiratory distress syndrome, Clinical trial, Advisory Committee, FDA, Animal, Pharmaceutical industry, Cryptocurrency, Audit, P.C, Dominion, Bankruptcy

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Fox News specifically called out Smartmatic and Dominion Voting Systems, voting technology and software companies, for their alleged involvement in rigging the election.
  • For more information on the Twist investigation go to: https://bespc.com/cases/TWST
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Veru Inc. - VERU

Retrieved on: 
Friday, November 18, 2022
COVID-19, Food, Patient, News, Defense Department Advisory Committee on Women in the Services, Advisory Committee, Acute respiratory distress syndrome, Pharmaceutical industry

NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. (Veru or the Company) (NASDAQ:VERU).

Key Points: 
  • NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. (Veru or the Company) (NASDAQ:VERU).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Veru and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Is Investigating Accelerate Diagnostics, and Veru and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, November 17, 2022
Marketing, COVID-19, Food, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Instil, News, Tobacco Products Scientific Advisory Committee, Acute respiratory distress syndrome, Advisory Committee, FDA, Pharmaceutical industry, Medical device, P.C

NEW YORK, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Accelerate Diagnostics, Inc. (NASDAQ: AXDX), and Veru Inc. (NASDAQ: VERU).

Key Points: 
  • NEW YORK, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Accelerate Diagnostics, Inc. (NASDAQ: AXDX), and Veru Inc. (NASDAQ: VERU).
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Previously, Accelerate Diagnostics had been marketing the Accelerate Arc products as Class I devices, exempting them from 510(k) clearance requirements.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

VERU ALERT: Bragar Eagel & Squire, P.C. is Investigating Veru Inc. on Behalf of Veru Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, November 15, 2022
Class Action Lawsuit, Professional Services, Legal, Tobacco Products Scientific Advisory Committee, News, Acute respiratory distress syndrome, COVID-19, Jeanne Eagels, P.C, Advisory Committee, Telephone, Food, Patient, Private investigator, Pharmaceutical industry, Verus

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Veru Inc. (Veru or the Company) (NASDAQ: VERU) on behalf of Veru stockholders.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Veru Inc. (Veru or the Company) (NASDAQ: VERU) on behalf of Veru stockholders.
  • Our investigation concerns whether Veru has violated the federal securities laws and/or engaged in other unlawful business practices.
  • Specifically, the Advisory Committee voted 8-5 that the known and potential benefits of sabizabulin do not outweigh its known and potential risks.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

NAMPT Inhibitors Market, Distribution by Type of Molecule, Therapeutic Area, Indication, Route of Administration, Line of Treatment, and Key Geographical Regions : Industry Trends and Global Forecasts, 2022-2040

Retrieved on: 
Friday, November 18, 2022
Table, Chapter Nine, Chapter Four, Chapter 13, Title 11, United States Code, Chapter 11, Title 11, United States Code, Chapter Seven, Hodgkin lymphoma, Interview, Therapy, Chapter Eight, Knowledge, Social media, Chapter Two, Chapter Five, Organization, Degenerative disease, Chapter 14, Partnership, FDA, 1997 Constitution of Fiji: Chapter 17, Acute myeloid leukemia, Forecasting, Research, Non-Hodgkin lymphoma, Chapter One, Chapter 16: The Rescue, Chapter Six, Chapter Ten, Publication, NAMPT, Chapter 12, Title 11, United States Code, Acute respiratory distress syndrome, Chapter Three, Map, Appendix, Chapter 15, Title 11, United States Code, Public relations, Pharmaceutical industry, Fine chemical

View original content:https://www.prnewswire.com/news-releases/nampt-inhibitors-market-distrib...

Key Points: 
  • What types of partnership models are commonly adopted by industry stakeholders engaged in this industry?
  • What are the strategic initiatives undertaken by players engaged in this market space related to research and development of NAMPT inhibitors?
  • This chapter further features details related to recent advancements that have been made in the NAMPT inhibitors market.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.